Replicor Inc.
PrivateLast Round
Series C
Aug 14, 2024
Total Funding Raised
$180M
Company Overview
Replicor Inc. is a biotechnology company that develops nucleic acid-based polymer therapeutics for the treatment of chronic hepatitis B and hepatitis delta virus infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Replicor Inc. Comparables
Compare Replicor Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AusperBio | 87% | |
| Mirum Pharmaceuticals | 82% | |
| Ionis Pharmaceuticals, Inc. | 79% | |
Replicor Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 14, 2024 | ||||
| Private Placement | Aug 5, 2021 |
Replicor Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARCH Venture Partners | Series C |
| Novo Holdings | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Monthly visitors grew 159% MoM.
- Oct 30, 2024
Monthly visitors grew 71% MoM, reaching 1.6K.
Replicor Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Replicor Inc.'s valuation, stock price, and market status.